Invivyd Reports Q4 2025 PEMGARDA Net Product Revenue of $17.2mln, 25% YoY Growth

• Invivyd reports Q4 2025 PEMGARDA net revenue of $17.2 million, up 25% YoY and 31% QoQ. • Ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million in 2H 2025. • Invivyd initiates DECLARATION Phase 3 clinical trial of VYD2311 to prevent COVID, with top-line data expected in mid-2026. • FDA grants Fast Track designation for VYD2311 in December 2025. • VBY329 nominated for preclinical development as potential best-in-class RSV antibody. • Preclinical measles mAb candidate selection targeted for 1H 2026.